Martin James Drysdale

This inventor holds 18 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Cancer Therapeutics. Top assignees: Cancer Research Technology Limited, The Institute of Cancer Research, Vernalis &r&d) Ltd.. Active years: 2007-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin James Drysdale. Retrieved from https://idiyas.com/inventor/martin-james-drysdale

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 3)

% Patents Active = 22.2

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 5.6

ph-index = 5

Forward Citations = 99(Granted Patents)

Location History:

Cambridge, GB (2007)
Berkshire, GB (2012 - 2013)
Abington, GB (2009 - 2017)
Winnersh, GB (2014 - 2017)
Great Abington, GB (2019 - 2022)

Company Filing History:

13 out of 269

Cancer Research Technology Limited

patents

11 out of 24

The Institute of Cancer Research

Vernalis (Cambridge) Limited

Institute of Cancer Research of Royal Cancer Hospital

patent

7. 1 out of 1

The Institute of Cancer

patent

8. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2022

Loading Chart...

Areas of Expertise:

Isoxazole Compounds

HSP90 Inhibitors

Indolyl-Pyridone Derivatives

Thieno[2,3-d]Pyrimidines

Pyrazole Compounds

Checkpoint Kinase 1

Heat Shock Proteins

Cancer Treatment

Pharmaceutical Formulations

Additive Salts

Hydrates

Polymorphs

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11234987 - Isoxazole compounds as inhibitors of heat shock proteins (2022-02-01),

2. 10696652 - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity (2020-06-30),

3. 10413550 - Isoxazole compounds as inhibitors of heat shock proteins (2019-09-17),

4. 9718793 - Isoxazole compounds as inhibitors of heat shock proteins (2017-08-01),

5. 9604975 - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity (2017-03-28),

6. 8916591 - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity (2014-12-23),

7. 8642594 - Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors (2014-02-04),

8. 8507480 - Isoxazole compounds as inhibitors of heat shock proteins (2013-08-13),

9. 8487095 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms (2013-07-16),

10. 8450310 - Isoxazole compounds as inhibitors of heat shock proteins (2013-05-28),

11. 8163747 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms (2012-04-24),

12. 7820658 - Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors (2010-10-26),

13. 7803831 - 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer (2010-09-28),

14. 7728016 - Substituted 5-membered ring compounds and their use (2010-06-01),

15. 7705027 - Isoxazole compounds as inhibitors of heat shock proteins (2010-04-27),

Title: Martin James Drysdale: Innovator in Cancer Research

Introduction

Martin James Drysdale is a prominent inventor based in Abington, GB. He has made significant contributions to the field of cancer research, holding a total of 18 patents. His work focuses on developing innovative compounds that target heat shock proteins and protein kinases, which are crucial in cancer treatment.

Latest Patents

Among his latest patents, Drysdale has developed isoxazole compounds that act as inhibitors of heat shock proteins. These compounds are particularly useful in treating various cancers. The isoxazoles he has formulated include complex structures that allow for targeted therapy. Additionally, he has created indolyl-pyridone derivatives that exhibit checkpoint kinase 1 inhibitory activity, providing a method for treating mammals suffering from cancers responsive to protein kinase inhibition.

Career Highlights

Throughout his career, Drysdale has worked with notable organizations such as Cancer Research Technology Limited and the Institute of Cancer Research. His work in these institutions has allowed him to advance his research and contribute to the development of effective cancer therapies.

Collaborations

Drysdale has collaborated with esteemed colleagues, including Brian William Dymock and Edward McDonald. These partnerships have fostered innovation and have been instrumental in his research endeavors.

Conclusion

Martin James Drysdale is a key figure in the field of cancer research, with a strong portfolio of patents that reflect his dedication to finding effective treatments. His innovative work continues to impact the medical community positively.

Profile summary based on public USPTO records.